Pemvidutide
Overview
Pemvidutide is a dual receptor agonist targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors, designed to combine the insulinotropic and appetite-suppressing effects of GLP-1 with the energy expenditure and lipolytic actions of glucagon. This balanced co-agonist strategy aims to achieve superior weight loss and metabolic benefits compared to GLP-1 monotherapy while mitigating the hyperglycemic effects of isolated glucagon receptor activation. The peptide architecture incorporates amino acid modifications to optimize receptor binding affinity and pharmacokinetic duration.
Key Research Findings
Phase 2 trial data presented at major endocrinology conferences in 2023 and 2024 reported substantial weight reductions exceeding 10 percent at 16 weeks in patients with obesity, along with improvements in lipid profiles and liver fat content. The compound is advancing through mid-stage development with ongoing trials in both obesity and metabolic dysfunction-associated steatohepatitis, though peer-reviewed publications are still emerging.
Subcutaneous injection
In Clinical Trials
Interested in Pemvidutide?
Find a verified provider experienced with Pemvidutide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Pemvidutide ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.